Drugs Made In America Acquisition Corp. (DMAAR) Cash from Financing Activities (2025)
Drugs Made In America Acquisition's (DMAAR) quarterly Cash from Financing Activities came in at $130600.0 in Q4 2025, up 133.2% quarter-over-quarter from $56003.0 in Q3 2025.
Powered by 
Analysis
Drugs Made In America Acquisition Corp. (DMAAR) Cash from Financing Activities (2025) Analysis & Trends
Drugs Made In America Acquisition (DMAAR) has reported Cash from Financing Activities for 1 consecutive years, with $130600.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities changed N/A year-over-year to $130600.0; the trailing twelve-month figure through Dec 2025 stood at $231.7 million (changed N/A YoY), and the FY2025 full-year result was $231.7 million, up 133351.97% from the prior year.
- Cash from Financing Activities rose to $130600.0 in Q4 2025 per DMAAR's latest filing, from $56003.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $231.4 million in Q1 2025 and bottomed at $56003.0 in Q3 2025.
Peer Set
Peer Comparison
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 130,600.00 |
| Sep 30, 2025 | 56,003.00 |
| Jun 30, 2025 | 106,554.00 |
| Mar 31, 2025 | 231.40 Mn |